# US 2015/0240236 A1 · Recombinant rna particles and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0240236 A1
- Document ID: US20150240236A1
- Status: Published application
- Kind: A1
- Application number: 14/622,671
- Filed: 2015-02-13
- Published: 2015-08-27
- Earliest claimed: 2014-02-13
- Assignees: Synthetic Genomics, Inc.
- Applicants: Synthetic Genomics, Inc.
- Inventors: ROBERT C. BROWN; KURT I. KAMRUD
- Web page: https://patentgrep.com/patent/US20150240236A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/86: Viral vectors
- C07K 2319/40: containing a tag for immunodetection, or an epitope for immunisation
- C07K 2319/60: containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2320/32: Special delivery means, e.g. tissue-specific
- C12N 2720/00022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2720/00043: viral genome or elements thereof as genetic vector
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention provides compositions and methods for the production and delivery of recombinant double-stranded RNA molecules (dsRNA) targeting pathogen sequences, which can be useful as an RNA vaccine. The compositions contain engineered double-stranded RNA particles (dsRPs) that can contain a double-stranded RNA molecule that can be a genome or portion of a genome, which can be enclosed in a capsid or coat protein. The dsRNA molecule also comprises an RNA sub-sequence that binds to a target sequence of a pathogenic organism. The dsRPs can be derived from wild-type viral organisms. The delivery of the dsRPs of the invention to an organism provides a protection to the organism from the pathogen.

## Claims

### Claim 1

A double-stranded RNA particle (dsRP) comprising a recombinant double-stranded RNA molecule (dsRNA) comprising at least one heterologous sub-sequence of RNA that binds to a target sequence.

### Claim 2 (depends on 1)

The dsRNA particle of claim 1 wherein the dsRNA particle is derived from L-A virus and is less than 100 nm in diameter.

### Claim 3 (depends on 2)

The dsRNA particle of claim 2 wherein the dsRNA molecule is less than about 6 kb.

### Claim 4 (depends on 1)

The dsRNA particle of claim 1 wherein the dsRNA molecule comprises RNA encoding for a Gag-Pol fusion protein.

### Claim 5 (depends on 1)

The dsRNA particle of claim 1 wherein the dsRNA molecule is encapsidated in a capsid.

### Claim 6 (depends on 1)

The dsRP of claim 1 wherein the target sequence is an RNA sequence coded for by a pathogen genome.

### Claim 7 (depends on 6)

The dsRP of claim 6 wherein the target sequence is a critical gene of the pathogen or a portion thereof.

### Claim 8 (depends on 6)

The dsRNA particle of claim 6 wherein the target sequence is a regulatory element of a gene that codes for a critical pathogen protein.

### Claim 9 (depends on 1)

The dsRNA particle of claim 1 wherein the target sequence is an RNA sequence of a pathogen that causes Infectious Pancreatic Necrosis (IPN) disease in salmonid fish.

### Claim 10 (depends on 1)

The dsRNA particle of claim 1 wherein the target sequence is an RNA sequence of a pathogen that causes white spot syndrome (WSS) in penaeid shrimp.

### Claim 11 (depends on 9)

The dsRNA particle of claim 9 wherein the target sequence is an RNA sequence coded for by a sequence selected from the group consisting of: an at least 10 bp portion of any one or more of the nucleotide sequences found in SEQ ID NOs: 2-103.

### Claim 12 (depends on 1)

The dsRNA particle of claim 1 wherein the target sequence is an RNA sequence of a pathogen that causes disease in an animal of the genus Sus.

### Claim 13 (depends on 8)

The dsRNA particle of claim 8 wherein the dsRNA particle provides an at least partial immunity in the salmonid fish against IPN for at least 60 days.

### Claim 14 (depends on 13)

The dsRNA particle of claim 13 wherein the dsRNA particle provides an at least partial immunity in the salmonid fish against IPN for at least 75 days.

### Claim 15 (depends on 8)

The dsRNA particle of claim 8 wherein the dsRNA particle provides an at least partial immunity in the penaeid shrimp against WSS for at least 7 days.

### Claim 16 (depends on 15)

The dsRNA particle of claim 15 wherein the dsRNA particle provides an at least partial immunity in the penaeid shrimp against WSS for at least 90 days.

### Claim 17 (depends on 12)

The dsRNA particle of claim 12 wherein the dsRNA particle provides an at least partial immunity in the animal of the genus Sus against said disease for at least 60 days.

### Claim 18 (depends on 1)

The dsRNA particle of claim 1 wherein the sub-sequence of RNA binds to an RNA target sequence and disrupts a critical function of a viral or bacterial pathogen.

### Claim 19 (depends on 1)

The dsRNA particle of claim 1 wherein the sub-sequence of RNA binds to an RNA target that is a unique sequence in a pathogen genome.

### Claim 20 (depends on 1)

The dsRNA particle of claim 1 wherein the RNA molecule further comprises a sequence complementary to the at least one heterologous sub-sequence of RNA, and a separator sequence located between the RNA sub-sequence and the complementary sequence so that the RNA sub-sequence and complementary sequence can bind and form a hairpin structure.

### Claim 21 (depends on 1)

A formulation comprising a dsRP of claim 1.

### Claim 22 (depends on 9)

A formulation comprising a dsRP of claim 9.

### Claim 23 (depends on 10)

A formulation comprising a dsRP of claim 10.

### Claim 24 (depends on 11)

A formulation comprising a dsRP of claim 11.

### Claim 25 (depends on 12)

A formulation comprising a dsRP of claim 12.

### Claim 26

A method of treating an animal disease comprising
administering to an animal to be treated a double-stranded RNA particle (dsRP) comprising a recombinant double-stranded RNA molecule (dsRNA) comprising at least one sub-sequence of RNA that binds to a target sequence.

### Claim 27 (depends on 26)

The method of claim 26 wherein the dsRP is derived from L-A virus and is less than 100 nm in diameter.

### Claim 28 (depends on 27)

The method of claim 27 wherein the animal is selected from the group consisting of: a peneid shrimp, a salmonid fish, or an animal of the genus Sus.

### Claim 29 (depends on 28)

The method of claim 28 wherein the animal is a peneid shrimp and the disease is white spot disease.
